Literature DB >> 25311352

SLNB in melanoma-DFS a true and cost-effective benefit?

Alexander C J van Akkooi1, Alexander M M Eggermont2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25311352     DOI： 10.1038/nrclinonc.2014.65-c3

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  11 in total

1.  MSLT-I-response of clinical trial investigators.

Authors:  Mark B Faries; Alistair J Cochran; John F Thompson
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

2.  Sentinel node followed by completion lymph node dissection versus nodal observation: staging or therapeutic? Controversy continues despite final results of MSLT-1.

Authors:  Alexander C J van Akkooi
Journal:  Melanoma Res       Date:  2014-08       Impact factor: 3.599

3.  Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention.

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-04-08       Impact factor: 66.675

4.  A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial.

Authors:  Lily L Altstein; Gang Li; Robert M Elashoff
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

5.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

6.  Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients.

Authors:  Christiane A Voit; Saskia L M Gooskens; Petra Siegel; Gregor Schaefer; Alfred Schoengen; Joachim Röwert; Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Eur J Cancer       Date:  2014-07-03       Impact factor: 9.162

7.  Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?

Authors:  Christiane A Voit; Alexander C J van Akkooi; Gregor Schäfer-Hesterberg; Alfred Schoengen; Paul I M Schmitz; Wolfram Sterry; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

8.  Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma.

Authors:  Christiane Voit; Alexander C J Van Akkooi; Gregor Schäfer-Hesterberg; Alfred Schoengen; Katharina Kowalczyk; Joachim C Roewert; Wolfram Sterry; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

Review 9.  Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma.

Authors:  Joseph Meirion Thomas
Journal:  J Plast Reconstr Aesthet Surg       Date:  2009-02-26       Impact factor: 2.740

10.  Potential cost-effectiveness of US-guided FNAC in melanoma patients as a primary procedure and in follow-up.

Authors:  Alexander C J van Akkooi; Christiane A Voit; Cornelis Verhoef; Alexander M M Eggermont
Journal:  Ann Surg Oncol       Date:  2010-02       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.